COMPASS Pathways plc
Every calculator, already run for CMPS
Open the full toolkit →You have the numbers on CMPS. Get the argument.
A written report on which of these readings actually decide the outcome for COMPASS Pathways plc, what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
16 analysts covering CMPSAnalyst Price Target Disagreement for COMPASS Pathways plc
Wall Street's bull case implies +333% from the current price; the bear case implies -13%. A 346% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for CMPS
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About COMPASS Pathways plc
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
CMPS — frequently asked
Is CMPS a buy right now?
Wall Street's consensus rating on COMPASS Pathways plc is Strong Buy across 16 analysts, with a mean price target of $23.75 (+58% vs. the current $15.01). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is CMPS overvalued?
CMPS trades at — trailing earnings, against a DCF fair value of $16 per share. The current price implies 5% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is CMPS's next earnings date?
COMPASS Pathways plc is next scheduled to report earnings around Nov 3, 2026. A full CMPS research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for COMPASS Pathways plc?
Analysts covering COMPASS Pathways plc (CMPS) range from a bear-case target of $13.00 to a bull-case high of $65.00, with a mean consensus target of $23.75 across 16 analysts. The spread of $52.00 (346% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare COMPASS Pathways plc against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For COMPASS Pathways plc
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full CMPS research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on COMPASS Pathways plc, in minutes. 3 free reports included with every account — no credit card required.